Malaria vaccine: Candidate antigens, mechanisms, constraints and prospects

被引:57
作者
Carvalho, LJM
Daniel-Ribeiro, CT
Goto, H
机构
[1] Fiocruz MS, Inst Oswaldo Cruz, WHO Collaborating Ctr Res & Training Immunol Para, Dept Immunol,Malaria Res Lab, BR-21045900 Rio De Janeiro, Brazil
[2] Univ Sao Paulo, Sao Paulo Inst Trop Med, Lab Soroepidemiol & Immunobiol, Sao Paulo, Brazil
[3] Univ Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil
关键词
D O I
10.1046/j.1365-3083.2002.01160.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
More than 30 years after the first report of successful vaccination against malaria using radiation-attenuated sporozoites, an effective malaria vaccine is not yet available. However, field and experimental data indicate that it can be developed. An astonishing amount of data has accumulated concerning parasite biology, host-parasite interaction, immunity and escape mechanisms, targets and modulators or immune responses. Nevertheless, so far this knowledge has not been enough to make us understand how to properly manipulate the whole system to build an effective vaccine. In this article, we describe candidate antigens, mechanisms, targets and trials performed with potential malaria vaccines and discuss the approaches, in vivo and in vitro models. constraints and how technologies such as DNA vaccination, genomics/protemics and reverse immunogenetics are providing exciting results and opening new doors to make malaria vaccine a realty.
引用
收藏
页码:327 / 343
页数:17
相关论文
共 135 条
[1]   Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania [J].
Acosta, CJ ;
Galindo, CM ;
Schellenberg, D ;
Aponte, JJ ;
Kahigwa, E ;
Urassa, H ;
Schellenberg, JRMA ;
Masanja, H ;
Hayes, R ;
Kitua, AY ;
Lwilla, F ;
Mshinda, H ;
Menendez, C ;
Tanner, M ;
Alonso, PL .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1999, 4 (05) :368-376
[2]  
ADA GL, 1997, VACCINES VACCINATION, P247
[3]  
[Anonymous], 1988, B WORLD HEALTH ORGAN, V66, P719
[4]   Plasmodium vivax malaria vaccine development [J].
Arévalo-Herrera, M ;
Herrera, S .
MOLECULAR IMMUNOLOGY, 2001, 38 (06) :443-455
[5]   AGE-SPECIFIC PREVALENCE OF PLASMODIUM-FALCIPARUM AMONG 6 POPULATIONS WITH LIMITED HISTORIES OF EXPOSURE TO ENDEMIC MALARIA [J].
BAIRD, JK ;
PURNOMO ;
BASRI, H ;
BANGS, MJ ;
ANDERSEN, EM ;
JONES, TR ;
MASBAR, S ;
HARJOSUWARNO, S ;
SUBIANTO, B ;
ARBANI, PR .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1993, 49 (06) :707-719
[6]   HOST AGE AS A DETERMINANT OF NATURALLY ACQUIRED-IMMUNITY TO PLASMODIUM-FALCIPARUM [J].
BAIRD, JK .
PARASITOLOGY TODAY, 1995, 11 (03) :105-111
[7]  
BALLOU WR, 1987, LANCET, V1, P1277
[8]   POLYCLONAL LYMPHOCYTE-B STIMULATION IN HUMAN MALARIA AND ITS ASSOCIATION WITH ONGOING PARASITEMIA [J].
BANIC, DM ;
VIANAMARTINS, FS ;
DESOUZA, JM ;
PEIXOTO, TD ;
DANIELRIBEIRO, C .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1991, 44 (05) :571-577
[9]   Immune response and lack of immune response to Plasmodium falciparum p126 antigen and its amino-terminal repeat in malaria-infected humans [J].
Banic, DM ;
De Oliveira-Ferreira, J ;
Pratt-Riccio, LR ;
Conseil, V ;
Gonçalves, D ;
Fialho, RR ;
Gras-Masse, H ;
Daniel-Ribeiro, CT ;
Camus, D .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1998, 58 (06) :768-774
[10]  
BANIC DM, IN PRESS AM J TROP M